CD20-directed Cytolytic Antibody [EPC]

323031 reported adverse events

Drugs of this class: OBINUTUZUMAB OCRELIZUMAB OCRELIZUMAB AND HYALURONIDASE OFATUMUMAB RITUXIMAB RITUXIMAB AND HYALURONIDASE RITUXIMAB-ABBS RITUXIMAB-ARRX RITUXIMAB-PVVR UBLITUXIMAB

These side effects are most commonly reported by patients taking drugs of the CD20-directed Cytolytic Antibody [EPC] class:

#	Side effect	Count
0	OFF LABEL USE	47313
1	DRUG INEFFECTIVE	37702
2	FATIGUE	29450
3	PAIN	24070
4	COVID-19	20958
5	RHEUMATOID ARTHRITIS	20123
6	HEADACHE	18167
7	PYREXIA	17873
8	INFUSION RELATED REACTION	17069
9	PNEUMONIA	16538

See all common reactions for CD20-directed Cytolytic Antibody [EPC]

Drugs of the CD20-directed Cytolytic Antibody [EPC] class are most commonly taken among patients reporting these side effects:

#	Side effect	Count	Frequency
0	ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE	5640	0.8267
1	VACCINE INTERACTION	239	0.7940
2	SWOLLEN JOINT COUNT INCREASED	2277	0.7716
3	PEMPHIGUS	9198	0.7700
4	RED BLOOD CELL SEDIMENTATION RATE	210	0.7581
5	SARS-COV-2 ANTIBODY TEST NEGATIVE	358	0.7537
6	RHEUMATIC FEVER	3100	0.7484
7	RHEUMATOID FACTOR POSITIVE	4128	0.7385
8	B-LYMPHOCYTE COUNT DECREASED	968	0.7361
9	C-REACTIVE PROTEIN	626	0.7229

See all enriched reactions for CD20-directed Cytolytic Antibody [EPC]